Education
About Us
Working with TipRanks
Follow Us
Merck & Company (DE:6MK)
:6MK
6MK Stock Chart & Stats
Day’s Range― - ―
52-Week Range€65.50 - €125.60
Previous CloseN/A
Volume75.00
Average Volume (3M)4.46K
Market Cap
€164.69B
Enterprise Value€216.98B
Total Cash (Recent Filing)€9.23B
Total Debt (Recent Filing)$34.84B
Price to Earnings (P/E)10.5
Beta0.34
Next Earnings
Jul 29, 2025EPS Estimate
1.84Last Dividend Ex-Date
Mar 17, 2025Dividend Yield4.3%
Share Statistics
EPS (TTM)1.98
Shares Outstanding2,511,031,300
10 Day Avg. Volume4,479
30 Day Avg. Volume4,460
Financial Highlights & Ratios
PEG Ratio5.72
Price to Book (P/B)3.98
Price to Sales (P/S)0.00
P/FCF Ratio11.20
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue0.86
Enterprise Value/Gross Profit4.19
Enterprise Value/Ebitda2.30
Forecast
1Y Price Target
€90.84Price Target Upside36.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
EarningsMerck beats on top (+1% vs. consensus) and bottom line (+4%) with relatively muted impacts to tariffs noted (~$200M).
Financial PerformanceMerck modestly beat revenue expectations driven partially by a ~15% beat for Winrevair with $280M in revenue for the quarter.
Growth PotentialAnalyst's recommendation is to buy MRK stock due to its undervaluation compared to its growth potential and full pipeline.
Bears Say
Market ChallengesContinued Gardasil overhang and pending competitor datasets for Keytruda could keep the share price performance sideways.
Product PerformanceKeytruda underperformed slightly (-3% vs. consensus) and Gardasil revenues in China continue to be more challenged (-10% vs. consensus).
Regulatory ChallengesSignificant uncertainty remains due to the Keytruda 2028 loss-of-exclusivity and other regulatory overhangs.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.05% Insiders
21.26%
Mutual Funds
1.02% Other Institutional Investors
54.01% Public Companies and
Individual Investors
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €65.50 and its highest was €125.60 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is €164.69B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Jul 29, 2025 which is in 73 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Apr 24, 2025. The company reported €1.984 earnings per share for the quarter, beating the consensus estimate of €1.907 by €0.078.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of €2.819 which represents an annual dividend yield of 4.3%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 1.84.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,511,031,300 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of €1.984 in its last earnings report, beating expectations of €1.907. Following the earnings report the stock price went down -0.577%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in DE:6MK
---
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€90.84 (36.39% Upside)
€90.84 (36.39% Upside)
Blogger Sentiment
Bullish
DE:6MK Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.53%
12-Months-Change
Fundamentals
Return on Equity
39.31%
Trailing 12-Months
Asset Growth
8.76%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
---
6MK Company Deck
---
6MK Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced view with strong emphasis on future growth potential through a robust pipeline and key product launches, while addressing challenges such as declining Gardasil sales in China and the impact of tariffs and foreign exchange. While there are significant growth drivers, the lowlights indicate notable challenges that could affect near-term performance.Read More>---
6MK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
---
6MK Stock 12 Month Forecast
Average Price Target
€90.84
▲(36.39% Upside)
Technical Analysis
---